COMMUNIQUÉS West-GlobeNewswire

-
HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder
10/01/2025 - 15:02 -
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
10/01/2025 - 15:00 -
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025
10/01/2025 - 15:00 -
ADARx Pharmaceuticals to Present at the J.P. Morgan 43ʳᵈ Annual Healthcare Conference
10/01/2025 - 15:00 -
Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD
10/01/2025 - 14:45 -
OneMedNet Regains Compliance with NASDAQ Minimum Bid Price Requirements
10/01/2025 - 14:45 -
Yerbaé Expands Distribution with Four New Partnerships, Creating Synergies with Safety Shot's Operations
10/01/2025 - 14:38 -
Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors
10/01/2025 - 14:30 -
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
10/01/2025 - 14:30 -
TOMI Environmental Solutions Positioned to Address Growing Global Disease Threats with SteraMist Technology
10/01/2025 - 14:30 -
NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million
10/01/2025 - 14:30 -
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
10/01/2025 - 14:30 -
InflammX Therapeutics Announces Option Agreement with Bausch + Lomb
10/01/2025 - 14:30 -
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
10/01/2025 - 14:30 -
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
10/01/2025 - 14:23 -
OrthoPediatrics Corp. Announces Expansion of Specialty Bracing Division
10/01/2025 - 14:05 -
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
10/01/2025 - 14:05 -
NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma
10/01/2025 - 14:03 -
RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025
10/01/2025 - 14:00
Pages